AAK1 inhibitors have been further developed to provide valuable treatments for disorders such as neuropathic pain, AD, and other neurodegenerative diseases (Abdel-Magid, 2017), indicating that AAK1 serves as a suitable biomarker of cognitive disorders, including VaD. This evidence concerns the gene AAK1 and Alzheimer disease.